Cytokinetics, Incorporated
CYTK
$43.27
-$0.61-1.39%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.93M | 463.00K | 249.00K | 835.00K | 1.67M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.93M | 463.00K | 249.00K | 835.00K | 1.67M |
| Cost of Revenue | 93.63M | 84.61M | 79.60M | 81.57M | 84.98M |
| Gross Profit | -76.70M | -84.15M | -79.35M | -80.74M | -83.30M |
| SG&A Expenses | 62.34M | 56.65M | 50.82M | 45.50M | 44.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 155.97M | 141.26M | 130.42M | 127.07M | 129.09M |
| Operating Income | -139.04M | -140.80M | -130.17M | -126.24M | -127.42M |
| Income Before Tax | -150.02M | -160.55M | -143.32M | -135.64M | -136.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -150.02M | -160.55M | -143.32M | -135.64M | -136.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -150.02M | -160.55M | -143.32M | -135.64M | -136.90M |
| EBIT | -139.04M | -140.80M | -130.17M | -126.24M | -127.42M |
| EBITDA | -136.66M | -138.39M | -127.77M | -123.90M | -121.08M |
| EPS Basic | -1.27 | -1.36 | -1.31 | -1.33 | -1.38 |
| Normalized Basic EPS | -0.79 | -0.85 | -0.82 | -0.83 | -0.86 |
| EPS Diluted | -1.27 | -1.36 | -1.31 | -1.33 | -1.38 |
| Normalized Diluted EPS | -0.79 | -0.85 | -0.82 | -0.83 | -0.86 |
| Average Basic Shares Outstanding | 118.08M | 117.69M | 109.24M | 101.92M | 99.07M |
| Average Diluted Shares Outstanding | 118.08M | 117.69M | 109.24M | 101.92M | 99.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
